A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

NCT06308406 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Ovarian Cancer

Interventions

DRUG: Bevacizumab； HRS-1167

Sponsor

Jiangsu HengRui Medicine Co., Ltd.